Introduction
============

Nonalcoholic fatty liver disease (NAFLD), a highly prevalent condition,[@b1-ijgm-4-717] is a feature of metabolic syndrome and characterized by excessive accumulation of fat in the liver cells.[@b2-ijgm-4-717],[@b3-ijgm-4-717] Patients with NAFLD have a higher mortality rate than the general population.[@b4-ijgm-4-717]

NAFLD is strongly associated with cardiovascular risk factors, such as obesity, dyslipidemia, type 2 diabetes mellitus, and insulin resistance.[@b5-ijgm-4-717] From previous published data, it is obvious that coronary heart disease mortality rates in patients with NAFLD are close to those associated with cirrhosis.[@b6-ijgm-4-717]

Ultrasonographic measurement of carotid intima-media thickness (CIMT) is a noninvasive method for demonstrating subclinical atherosclerosis. Increased CIMT has a significant relationship with the presence and severity of coronary atherosclerosis.[@b7-ijgm-4-717],[@b8-ijgm-4-717]

In recent years, case-control studies have shown a relationship between NAFLD and the presence of early manifestations of atherosclerosis indicated by CIMT measurement.[@b8-ijgm-4-717],[@b9-ijgm-4-717] Other studies have shown only a relationship between NAFLD and advanced atherosclerosis, such as carotid plaque.[@b10-ijgm-4-717],[@b11-ijgm-4-717] However, the association between CIMT and NAFLD requires further investigation because metabolic syndrome comprises multiple risk factors for coronary artery disease, which may have confounded the results of studies published to date.

In the present study, we investigated the association between NAFLD as a risk factor for atherosclerosis and CIMT by comparing a group of outpatients with NAFLD confirmed incidentally on ultrasonography and a control group with ultrasonographically normal liver echogenicity. Independent evaluation of CIMT in patients with NAFLD and other cardiovascular risk factors is the novelty of our present research.

Materials and methods
=====================

We examined 250 consecutive patients with incidental ultra-sonographically confirmed NAFLD and 85 age-matched and gender-matched control subjects with normal parenchymal liver echogenicity for determination of CIMT and presence of carotid atherosclerotic plaque. The patients were referred to the Radiology Department from the Gastroenterology Outpatient Clinic at the University Training Hospital for measurement of CIMT after abdominal ultrasonography was performed for nonspecific abdominal discomfort, and diagnosis of fatty liver was made according to ultrasonographic examination. All of the abdominal sonograms were performed by one radiologist (AH). Thirty-five patients with NAFLD were excluded from the study because they failed to meet the inclusion criteria. Exclusion criteria were heart disease, diabetes mellitus, acute or chronic liver disease, acute or chronic kidney disease, any malignancy, alcohol consumption, pregnancy, liver masses, abnormal copper metabolism or thyroid function test, history of any medication with adverse effects on the liver, and a history of cigarette smoking. Only hepatitis B surface antigen-negative and hepatitis C antibody-negative patients were enrolled.

Hypertension was diagnosed as blood pressure \>140/90 mmHg or the taking of antihypertensive drugs. Body mass index was calculated by dividing weight in kilograms by height in meters squared. Blood samples were collected in the morning after an overnight fast. Blood was tested for fasting glucose (normal range \<126 mg/dL), triglycerides (normal range \<200 mg/dL), total cholesterol (normal range \<240 mg/dL), high-density lipoproteins, C-reactive protein, mean platelet volume, and serum transaminases (alanine aminotransferase and aspartate aminotransferase). All blood samples were tested in the same laboratory.

High resolution B mode ultrasonography of both the common and internal carotid arteries was performed using an ultrasound machine (Sonoline G40; Siemens, Munich, Germany) equipped with a 10 mHz linear array transducer. Patients were examined in the supine position with the head tilted backwards. After the carotid arteries were located by transverse scans, the probe was rotated to 90° to obtain and record a longitudinal image of the common carotid arteries.

The maximum CIMT was measured at the posterior wall of the common carotid artery, 2 cm before the bifurcation, as the distance between the first and second echogenic lines of the anterior and posterior arterial walls. The image was focused on the posterior wall of the common carotid artery, and gain settings were used to optimize image quality. Measurement was performed vertical to the arterial wall for accurate measurement of CIMT ([Figure 1](#f1-ijgm-4-717){ref-type="fig"}). Three CIMT measurements were taken at each site and the average measurement was used. The CIMT was assessed as being normal if it did not exceed 0.7 mm.[@b7-ijgm-4-717] All of the CIMT measurement sonograms were obtained by another radiologist blinded to the results of abdominal sonography and the clinical and laboratory data for cases and control subjects.

The anterior and posterior walls of the common carotid arteries, internal carotid arteries, and carotid bulbs were evaluated for determination of presence of carotid plaque, defined as a focal thickening \>1.2 mm of the intima-media complex, measured from the media-adventitia interface to the intima-lumen interface ([Figure 2](#f2-ijgm-4-717){ref-type="fig"}). One radiologist experienced in Doppler evaluation of the extracranial vessels, who had no prior knowledge of the patient clinical and laboratory data, performed the ultrasonographic examinations.

Abdominal ultrasound scanning was performed in all participants by another trained radiologist, who was blinded to all patient clinical and laboratory data, using a Toshiba Nemio 30 scanner (Toshiba Co Ltd, Tokyo, Japan) with a 3.5 mHz linear transducer. Hepatic steatosis was diagnosed by a characteristic liver echo pattern as evidence of diffuse hyperechogenicity of the liver relative to the right kidney. The patients were divided into three groups based on the degree of fatty infiltration, ie, mild fatty liver (grade 1), moderate fatty liver (grade 2), and severe fatty liver (grade 3) according to the ultrasound appearance of hepatosteatosis. In grade 1 (mild) fatty infiltration, echogenicity was slightly increased, with normal visualization of the diaphragm and the intrahepatic vessel borders. Grade 2 (moderate) fatty infiltration was established when echogenicity was moderately increased, with slightly impaired visualization of the diaphragm or intrahepatic vessels. In grade 3 (severe) fatty infiltration, echogenicity was markedly increased with poor visualization of the diaphragm, intrahepatic vessels, and posterior portion of the right lobe. The study was approved by the institutional review board of the university, and all the participants provided their written informed consent.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software (v 16; SPSS Inc, Chicago, IL). Statistical significance was set at a two-sided *P* value of ≤0.05. Results are reported as the mean ± standard deviation, n (%) for continuous variables, and as frequencies for categorical variables. For comparison of patient and control data, one-way analysis of variance and *t*-testing were used for quantitative variables, and the Chisquare test was used to determine the statistical significance of differences in qualitative variables. The relationship for continuous variables was examined by Pearson's correlation coefficients and categorical variables by Spearman correlation analysis. Thereafter, one-way analysis of variance was utilized to compare different variables (including intimamedia thickness, fasting blood sugar, triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, alanine aminotransferase, aspartate aminotransferase, mean platelet volume, and body mass index) with the different grades of fatty liver disease. Multivariate modeling was done by linear regression analysis. In multivariate analysis, the presence of NAFLD was an independent variable and regression analysis was used.

Results
=======

We examined 250 patients with NAFLD (139 male and 111 female) and 85 controls (46 male and 39 female). Because of the study design, cases and control subjects were almost identical in terms of gender and age. The mean age of patients with NAFLD was 46.5 ± 10.5 years and for controls was 44.8 ± 14.1 (*P* = 0.078).

Patients with NAFLD had a higher frequency of elevated blood pressure than normal subjects (40% vs 15.2%). This difference was statistically significant (*P* = 0.001). Mean fasting blood glucose was significantly (*P* = 0.001) higher in patients with NAFLD (117.16) than in normal subjects (90.77). Levels of aspartate aminotransferase (*P* = 0.006), alanine aminotransferase, mean platelet volume, and C-reactive protein were higher in patients with NAFLD than in the control group (*P* = 0.001). In patients with NAFLD, serum triglyceride and total cholesterol levels were higher (*P* = 0.001) and high-density lipoprotein cholesterol was lower (*P* = 0.001) than in control subjects. Patients with NAFLD had a significant higher body mass index than controls. The mean body mass index in patients with NAFLD was 29.88 ± 3.88 kg/m^2^ and in the control group was 25.29 ± 4.19 kg/m^2^; this difference was statistically significant (*P* = 0.001). Patients with NAFLD had a greater mean CIMT (0.81 ± 0.14 mm) than control subjects (0.58 ± 0.15 mm); this difference was statistically significant (*P* = 0.001). The frequency of carotid plaque in patients with NAFLD was 1.7-fold higher than in controls (*P* = 0.176). All risk factors related to metabolic syndrome (body mass index, hypertension, glucose level, hypertriglyceridemia, and high-density lipoprotein cholesterol) were significantly greater in patients with NAFLD than in control subjects (*P* = 0.001).

[Table 1](#t1-ijgm-4-717){ref-type="table"} shows the main clinical, ultrasonographic, and laboratory data for the patients and control subjects. In controls, the mean value of CIMT in men was 0.56 ± 0.14 mm and in women was 0.61 ± 0.16 mm; this difference was not statistically significant (*P* = 0.09). In patients with NAFLD, mean CIMT in men was 0.79 ± 0.12 mm and in women was 0.84 ± 0.17 mm; this difference was statistically significant (*P* = 0.019). Furthermore, after adjustment for multiple confounding factors, such as hypertension, diabetes mellitus, hypertriglyceridemia, hypercholesterolemia, and hyperglycemia, the mean CIMT in control subjects was 0.56 ± 0.13 mm and in patients with NAFLD was 0.76 ± 0.09 mm, which was a statistically significant difference (*P* = 0.001). The presence of NAFLD was found to be associated with abnormal CIMT independent of other atherogenic risk factors. After adjustment for multiple confounding factors, mean CIMT in men with NAFLD was 0.75 ± 0.08 mm and in women with NAFLD was 0.77 ± 0.1 mm, which was not a statistically significant difference (*P* = 0.36).

In Pearson analysis, there was a strong positive correlation between CIMT and mean platelet volume (*r* = 0.18, *P* = 0.0001), fasting blood sugar (*r* = 0.18, *P* = 0.0001), triglycerides (*r* = 0.18, *P* = 0.0001), total cholesterol (*r* = 0.19, *P* = 0.0001), body mass index (*r* = 0.39, *P* = 0.0001), and age (*r* = 0.44, *P* = 0.0001), and there was a strong negative correlation between high-density lipoprotein cholesterol and CIMT (*r* = −0.32, *P* = 0.0001). In multivariate linear regression analysis, the presence of elevated C-reactive protein (*P* = 0.006) hypertension (*P* = 0.005), and a combination of hypertension and elevated C-reactive protein were independent risk factors affecting CIMT (*P* = 0.003).

Discussion
==========

NAFLD is defined as excessive accumulation of fat in hepatocytes and has a range of pathologic presentations, ranging from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD is 20%--30% in the general adult population in Western countries[@b12-ijgm-4-717] and is now 12%--24% in Asian-Pacific countries.[@b13-ijgm-4-717] Its prevalence in obese or diabetic patients increases up to 70%--90%.[@b12-ijgm-4-717]

Although the exact pathophysiologic basis of NAFLD is not well understood, several investigations have suggested that excessive accumulation of triglycerides in hepatocytes due to insulin resistance is the first step, and that oxidative stress reactions resulting from mitochondrial fatty acid oxidation and expression of inflammatory cytokines and adipocytokines are other potential factors which cause hepatocyte injury, inflammation, and fibrosis.[@b14-ijgm-4-717]

Our study revealed that the C-reactive protein level in patients with NAFLD was higher than in control subjects (*P* = 0.001). This finding suggests that the inflammatory state caused by excessive oxidative stress reactions may contribute to hepatic injury in patients with NAFLD. The main risk factors associated with NAFLD are increased bodyweight, diabetes mellitus, hyperlipidemia, and metabolic syndrome.[@b5-ijgm-4-717] Approximately 90% of patients with NAFLD have at least one characteristic feature of metabolic syndrome and about 33% have the full complement of features.[@b15-ijgm-4-717],[@b16-ijgm-4-717] This strong association suggests that NAFLD may have a potential role in the development and progression of atherosclerosis. Some investigations suggest that the outcome in patients with NAFLD is more dependent on cardiovascular events than on the progression of liver disease.[@b17-ijgm-4-717]--[@b19-ijgm-4-717]

Previous investigations have demonstrated a strong relationship between CIMT and the risk of myocardial and cerebral infarction, and CIMT can identify patients at high risk for coronary artery disease effectively.[@b20-ijgm-4-717],[@b21-ijgm-4-717] Patients with a mean CIMT \>1.15 mm have been reported to have a 94% likelihood of having coronary artery disease.[@b21-ijgm-4-717] Many studies have evaluated the relationship between atherosclerotic risk factors and CIMT, and confirmed that CIMT thickness increases with age, gender, hypertension, diabetes mellitus, and hyperlipidemia.[@b22-ijgm-4-717],[@b23-ijgm-4-717]

In this case-control study, we evaluated carotid atherosclerosis by measuring CIMT as an indicator of cardiovascular risk in patients with incidental ultrasonographically confirmed fatty liver. We established the diagnosis of NAFLD according to ultrasonographic appearance and exclusion of other known etiologies of chronic liver disease. The diagnosis was not confirmed by liver biopsy for ethical reasons. Ultrasonography can detect increased liver echogenicity and confirm the diagnosis of NAFLD, particularly when hepatic fat infiltration is more than 33%.[@b24-ijgm-4-717] In this study, CIMT in patients with NAFLD was significantly higher than in a gender-matched and age-matched control group (*P* = 0.001). When compared with control subjects, women with NAFLD had a mean CIMT even higher than men with NAFLD (*P* = 0.019).

Our study found no gender-related difference in mean CIMT for patients with NAFLD and without metabolic syndrome, but the mean CIMT in female patients with NAFLD was higher than for male patients with metabolic syndrome (*P* = 0.019). This finding is similar to those of studies that showed several metabolic traits[@b25-ijgm-4-717] for the metabolic syndrome to have greater atherogenic effects on women than in men.[@b26-ijgm-4-717],[@b27-ijgm-4-717]

Our study revealed an association between incidentally diagnosed NAFLD and CIMT, but no significant relationship between carotid plaque and NAFLD. Many studies have demonstrated an association between NAFLD and CIMT.[@b28-ijgm-4-717],[@b29-ijgm-4-717] Volzke et al showed that there is an independent association between hepatic steatosis and carotid plaques, but not with CIMT.[@b30-ijgm-4-717] Although in our study the body mass index in controls and patients with NAFLD was different, and previous data have shown that there is a relationship between body mass index and CIMT,[@b31-ijgm-4-717]--[@b33-ijgm-4-717] our data confirm that most of the adverse effects of obesity are due to a high prevalence of hypertension and hyperglycemia, because these patients had a higher prevalence of cardiovascular risk factors and showed signs of early atherosclerosis.

We measured mean CIMT in the posterior wall of both common carotid arteries because this location is more reliable and more easily accessed compared with other carotid segments. Previous research has shown that collection of data from all carotid segments can predict cardiovascular risk more accurately than collection of data from only the common carotid.[@b25-ijgm-4-717] Therefore, our study may have a potential limitation in estimation of the relationship between NAFLD and risk of cardiovascular events.

In conclusion, NAFLD may be an independent risk factor for developing atherosclerosis. Therefore, NAFLD without other cardiovascular risk factors can be associated with increased CIMT and increased risk of cardiovascular events in patients with NAFLD incidentally diagnosed on abdominal ultrasonography. NAFLD may serve as a trigger for assessment of silent carotid lesions and cardiovascular risk factors, and such patients should undergo further cardiovascular assessment.
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![Longitudinal sonogram shows that the CIMT is 1.1 mm in a patient with NAFLD.](ijgm-4-717f1){#f1-ijgm-4-717}

![Longitudinal sonogram shows the presence of a soft hypoechoic carotid plaque in anterior wall of common carotid artery (CCA).](ijgm-4-717f2){#f2-ijgm-4-717}

###### 

Main clinical, ultrasonographic, and laboratory data for patients with NAFLD and control subjects

  Variable                    NAFLD             Control           *P* value
  --------------------------- ----------------- ----------------- -----------
  Number                      250               85                
  Sex (M)                     139               46                0.9
  Age (years)                 46.58 (±10.4)     44.85 (±14.17)    0.028
  Weight (kg)                 83.90 (±9.53)     70.3 (±11.27)     0.001
  BMI (kg/m^2^)               29.88 (±3.88)     25.29 (±4.19)     0.001
  ALT                         30.10 (±33.47)    19.82 (±11.98)    0.006
  AST                         37.23 (±26.64)    22.29 (±10.73)    0.001
  TG (mg/dL)                  189.14 (±88.1)    107.05 (±36.97)   0.001
  Total cholesterol (mg/dL)   207.71 (±49.81)   163.83 (±34.50)   0.001
  HDL (mg/L)                  41.05 (±8.62)     52.69 (±9.03)     0.001
  MPV (fL)                    10.51 (±2.86)     9.10 (±1.12)      0.001
  CRP (+)                     22.4%             3.5%              0.001
  HTN (+)                     40.8%             15.2%             0.001
  Plaque (+)                  20%               11.7%             0.176
  FBS (mg/L)                  117.16 (±61.52)   90.77 (±15.10)    0.001
  IMT (mm)                    0.81(±0.14)       0.58 (±0.15)      0.001

**Abbreviations:** BMI, body mass index; TG, triglycerides; HDL, high-density lipoprotein; CRP, C-reactive protein; HTN, hypertension; FBS, fasting blood glucose; IMT, intima-media thickness; MPV, mean platelet volume; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAFLD, nonalcoholic fatty liver disease.
